Background/Purpose: Over the last five years the concept of “Treat to Target” has been accepted internationally and is gaining momentum in the United States (US). In a real world (RW) setting however, rheumatologists have been slow to consistently obtain and utilize objective outcome measures.  It is currently estimated that approximately 50 percent of US rheumatologists are obtaining outcome measures and of those, approximately one third are using the outcome measures in treatment decisions. The RAPID3 is a pooled index of the 3 patient-reported American College of Rheumatology Core Data Set measures. It has been validated against the Disease Activity Score (DAS-28) and Clinical Disease Activity Index (CDAI). The goal, to compare high, moderate, low and remission categories of RAPID3 to DAS28, DAS28-CRP, CDAI and the Simplified Disease Activity Index (SDAI) in RA patients enrolled in the JointMan registry (JM). JM captures RA criteria, disease features, joint counts, outcome measures, serology, medication efficacy and safety.

Methods: Retrospective registry review of data from 22 US rheumatologists. All 5 outcomes were available in 4241 patients over 22876 visits from 2009 to 2016. Standard score ranges for measures were used. All five metrics were compared against each other using the Pearson’s and Spearman’s correlations.

Results: RAPID3 scores correlated significantly (p <0.0001) with all other scores using both Pearson’s and Spearman’s correlation coefficients. Overall, 65.5% of patients who met DAS28/CDAI moderate/high activity criteria met similar RAPID3 severity criteria; 47.5% who met RAPID3 remission/low activity criteria met similar DAS28/CDAI criteria.

Conclusion: In JM, the RAPID3 correlated with the CDAI and the SDAI strongly. RAPID3 correlated with the DAS28 and the DAS28-CRP at a moderate /low level. This data support continued use of the RAPID3 as an outcome measure and is the first publication validating the RAPID3 with the SDAI in a RW setting.